Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011
In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
April 14, 2010 / Pharmacogenomics Reporter - Q&A: Diaceutics CEO Keeling Provides Personalized Rx-Focused Consultant's View of Industry Progress
February 22, 2012 / Pharmacogenomics Reporter - Personalized Medicine in 2011: Some Successes, Slow Progress, Continued Economic Woes
January 4, 2012 / Pharmacogenomics Reporter - Next-Gen Sequencing: Hot as a Research Tool; Not for Qiagen's Companion Dx Strategy
July 20, 2011 / Pharmacogenomics Reporter